Predictive Value of Renal Venous Flow Profiles for Adverse Outcomes in Right Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

421 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-11-30

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Predictive value of renal venous flow profiles for adverse outcomes in patients with right heart failure

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Kidney Disease and Pulmonary Hypertension

NCT03045614

Pulmonary Hypertension

COMPLETED

Renal Venous Flow and Cardiac Surgery-associated Acute Kidney Injury

NCT03753607

Acute Kidney Injury Cardiorenal Syndrome

COMPLETED

Arterial Stiffness, Wave Reflections and Renal Failure

NCT00354588

Chronic Renal Failure Arterial Stiffness Arterial Wave Reflections

COMPLETED

Renal Hemodynamics in Patients With HFpEF

NCT03672591

Heart Failure With Normal Ejection Fraction

COMPLETED

DKK3 for Prognosis and Monitoring of GFR Decline in Heart Failure

NCT04111094

Heart Failure Chronic Kidney Diseases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Persistent congestion with deteriorating renal function is an important cause of adverse outcomes in heart failure. The investigators aimed to characterize new Doppler ultrasonography approaches to evaluate the continuum of renal congestion. Pulmonary hypertension is the most common precursor to right heart failure and thus represents an ideal scenario to study congestion. The second cohort comprises consecutive Cardiology inpatients aged ≥18 years with a new or pre-existing diagnosis of heart failure who are referred to the consultant nephrologist with a history of diuretic-resistant fluid overload and impaired renal function. The investigators choose patients with heart failure to broaden the findings to the most common clinical entity of right ventricular failure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Hypertension Cardiorenal Syndrome Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary hypertension cohort

Consecutive adult Pulmonology inpatients with suspected or pre-diagnosed pulmonary hypertension undergoing invasive right heart catheterization.

No intervention

Intervention Type DIAGNOSTIC_TEST

No intervention

Heart failure cohort

Consecutive adult Cardiology inpatients with a new or pre-existing diagnosis of heart failure who are referred to the consultant nephrologist with a history of diuretic-resistant fluid overload and impaired renal function.

No intervention

Intervention Type DIAGNOSTIC_TEST

No intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

* CKD stage 5 (KDIGO)
* pre-existing acute kidney injury (acute kidney injury was defined as an increase in serum creatinine by ≥ 0.3 mg/dl within 48 hours or to ≥ 1.5 times baseline within the prior 7 days, as determined by all available serum creatinine values from hospital and outpatient medical records within the previous 90 days)
* Non-end stage renal disease patients with extracorporeal or peritoneal ultrafiltration for treatment of diuretic-resistant fluid overload
* Patients with primary kidney disease (e.g., glomerulonephritis, autosomal dominant polycystic kidney disease, postrenal obstruction)
* solid-organ transplant recipients
* use of non-steroidal inflammatory drugs within 72 hours before right heart catheterization

Heart failure cohort:

* Patients with mechanical assist devices are excluded

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No